Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida(Memorial Sloan Kettering Cancer Center), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Anuradha Gopalan(Memorial Sloan Kettering Cancer Center), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), Ahmet Zehir(Natera (United States)), Michael J. Morris(Dana-Farber Cancer Institute), Emily Carbone(Memorial Sloan Kettering Cancer Center), Joshua Armenia(AstraZeneca (United Kingdom)), Jaclyn F. Hechtman(Caris Life Sciences (United States)), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center), Daniel C. Danila, Michael F. Berger(Memorial Sloan Kettering Cancer Center), Susan F. Slovin(Cornell University), Preethi Srinivasan(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci, Vincent P. Laudone(Memorial Sloan Kettering Cancer Center), Sumit Middha(Memorial Sloan Kettering Cancer Center), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Philip W. Kantoff(Convergent Science (United States)), Philip Jonsson(Memorial Sloan Kettering Cancer Center), Melanie Hullings(Memorial Sloan Kettering Cancer Center), Zsofia K. Stadler(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Karen A. Autio(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Ethan Barnett(Memorial Sloan Kettering Cancer Center), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Michael L. Cheng(University of California, San Francisco), Hebert Alberto Vargas(NYU Langone Health)
Cited by 661
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k